← All trials
NCT05020392
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 14, 2021
- Primary completion
- Oct 13, 2023
- Completion date
- Oct 13, 2024
- First posted
- Aug 25, 2021
- Last posted
- Oct 21, 2021
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Huazhong University of Science and TechnologyReponsible party - principal investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Wuhan Sian Medical Technology Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.